Literature DB >> 3608350

Clinical pharmacology of torasemide, a new loop diuretic.

D C Brater, J Leinfelder, S A Anderson.   

Abstract

Torasemide is a new loop diuretic that potentially may have renal tubular effects from both the blood and urinary sides of the nephron. We assessed its pharmacokinetics and pharmacodynamics in eight normal subjects administering intravenous doses of 5, 10, and 20 mg compared with 40 mg furosemide. We assessed the effect of probenecid on response to the 20 mg dose. A dose intermediate to the 10 and 20 mg doses appeared equally natriuretic to 40 mg furosemide. Although total clearance was the same with all doses (about 0.45 ml/min/kg), renal clearance and the fraction of unchanged drug appearing in the urine decreased with higher doses raising the question of saturable renal secretion. Urinary dose-response curves showed torasemide to be five times as potent as furosemide. Probenecid pretreatment decreased both urine volume (P = 0.0016) and sodium excretion (P = 0.0003), implying that delivery of drug to the urinary side of the nephron is the major determinant of response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608350     DOI: 10.1038/clpt.1987.131

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.

Authors:  H Knauf; H Spahn; E Mutschler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide.

Authors:  T Risler; B Krämer; G A Müller
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 7.  Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Authors:  D C Brater
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

8.  Torasemide in the treatment of patients with cirrhosis and ascites.

Authors:  P Gentilini; G Laffi; G La Villa; V Carloni; M Foschi; R G Romanelli; F Marra
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

9.  Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation.

Authors:  D C Brater; D R Rudy; J R Voelker; P K Greene; T Gehr; D A Sica
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 10.  Torasemide in advanced renal failure.

Authors:  J Kindler
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.